 BEDMER, N.J.--BUSINESS WIRE--- TYME--Tyme Technologies, Inc. NASDAQ: TYME, an emerging biotechnology company developing cancer metabolism-based therapies CMBTsTM, announced that an abstract highlighting clinical data for TYMEs lead candidate, oral SM-88 racemetyrosine, in patients with metastatic pancreatic cancer, has been selected for poster presentation at the American Society of Clinical Oncology ASCO Virtual 2021 Gastrointestinal Cancers Symposium being held on January 15 - 17, 2021. 